Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is thought to exert its effects by enhancing the activity of the neurotransmitter gamma-aminobutyric acid (GABA).
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric and adult patients.
## Adult Dosing
* **Initial dose:** 5 mg twice daily.
* **Titration:** May be increased by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maintenance dose:** Typically ranges from 10 mg to 20 mg twice daily.
* **Maximum dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing
Dosing for pediatric patients requires careful titration and monitoring due to potential for increased sensitivity.
* **Patients 2 years and older and weighing less than 30 kg:**
* **Initial dose:** 5 mg once daily.
* **Titration:** May be increased by 2.5 mg to 5 mg every week based on clinical response and tolerability.
* **Maintenance dose:** Typically ranges from 5 mg to 10 mg once or twice daily.
* **Maximum dose:** 10 mg twice daily (20 mg/day).
* **Patients 2 years and older and weighing 30 kg or more:**
* **Initial dose:** 5 mg twice daily.
* **Titration:** May be increased by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maintenance dose:** Typically ranges from 10 mg to 20 mg twice daily.
* **Maximum dose:** 20 mg twice daily (40 mg/day).
*Note: Dosing for children younger than 2 years of age has not been established.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Consider a lower starting dose and slower titration.
* **Renal Impairment:** Use with caution. Dose adjustment may be necessary, particularly in severe impairment.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Myasthenia gravis.
* Acute narrow-angle glaucoma.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, aggression, irritability, constipation, and vomiting. Serious adverse effects can include severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, and withdrawal symptoms upon discontinuation.
## Key Drug Interactions
* **CYP3A4 inhibitors/inducers:** Clobazam is metabolized by CYP2C19. Co-administration with strong CYP2C19 inhibitors (e.g., fluconazole) may increase clobazam levels. Strong CYP2C19 inducers (e.g., rifampin) may decrease levels.
* **CNS Depressants:** Additive CNS depression may occur with alcohol, opioids, other benzodiazepines, and other sedating medications.
* **Other Anticonvulsants:** Clobazam can affect levels of other anticonvulsants; monitor for efficacy and toxicity.
## Monitoring
* Monitor for efficacy (seizure frequency).
* Monitor for adverse effects, particularly somnolence, dizziness, behavioral changes, and signs of severe skin reactions.
* Monitor for signs of withdrawal if the dose is reduced or discontinued.
* Consider monitoring clobazam and N-desmethylclobazam (active metabolite) levels, especially with interacting medications or suspected toxicity.
## Clinical Pearls
* Clobazam is indicated as adjunctive therapy for LGS seizures and should not be used as monotherapy.
* Gradual dose reduction is necessary when discontinuing clobazam to avoid withdrawal symptoms.
* Be aware of the potential for increased risk of serious skin reactions, especially early in treatment. Patients should be instructed to seek immediate medical attention if a rash develops.
* Behavioral and psychiatric changes can occur; consider dose reduction or discontinuation if these are severe or persistent.
***
*Disclaimer: This information is intended for clinical use and does not replace professional medical judgment. Always consult the most current prescribing information and relevant guidelines for definitive patient management.*
